Healthcare Industry News: dihydroergotamine
News Release - August 10, 2007
MAP Pharmaceuticals Appoints Shashidhar Kori New Vice President of Clinical DevelopmentMOUNTAIN VIEW, Calif., Aug. 10 (HSMN NewsFeed) -- MAP Pharmaceuticals, Inc. today announced the appointment of Dr. Shashidhar Kori, M.D. to the position of Vice President of Clinical Development.
Dr. Kori has spent over 30 years in drug development and academic research in the field of neurology. Most recently, Dr. Kori worked at GlaxoSmithKline PLC as Senior Director, Clinical Development and Senior Medical Advisor on the Pain/Migraine Team. In this role, Dr. Kori oversaw the design and execution of clinical studies and coordinated responses to FDA for migraine and pain products in development. In addition, he served as liaison to the external scientific and medical community, including leading headache specialists, participated in the development of new chemical entities and managed market support for marketed products.
In his new role, Dr. Kori will oversee development and execution of the Phase 3 clinical trials for MAP Pharmaceuticals' lead migraine candidate, MAP0004. Dr. Kori will direct the initiation, execution and evaluation of clinical trials, and lead clinical interactions with global regulatory authorities and multidisciplinary commercial, regulatory and business development interactions at the Company.
"Dr. Kori is widely recognized and respected in the field of neurology and neuroscience, migraine in particular," said Stephen B. Shrewsbury, M.B. Ch.B., Chief Medical Officer of MAP Pharmaceuticals. "We are pleased he will be bringing to the Company his wealth of neuropharmacology experience, including several years of work with one of the pre-eminent pharmaceutical companies, which is a worldwide leader in migraine therapy. As we broaden our scope of therapeutic opportunities, Shashi's role will be to oversee clinical development and to develop strategic and operational plans for the department. We are fortunate to have someone of his caliber join MAP Pharmaceuticals in such a key position at this important point in our history."
In addition to his experience in drug development, Dr. Kori has a distinguished academic career, having held posts at Duke University, the University of South Florida College of Medicine and Case Western Reserve University. He also served as Director of the Pain and Palliative Care Center at Duke University Medical Center. Dr. Kori has held numerous administrative and leadership positions in professional organizations, including the American Academy of Neurology, Southern Pain Society, American Society for Neuroimaging and South Eastern Academic Pain Consortium. Dr. Kori has authored over 80 publications and frequently speaks at major international meetings on migraine and pain management.
About MAP Pharmaceuticals
Located in Mountain View, California, MAP Pharmaceuticals, Inc. uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. The Company has several proprietary product candidates in clinical development that address large market opportunities, including the two most advanced product candidates: a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma, and a proprietary formulation of inhaled dihydroergotamine for the potential treatment of migraine. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
This news release may contain forward-looking statements, including with respect to the progress of the Company's clinical trials and the scope of the Company's clinical and product development programs. These statements involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital and dependence upon collaborators. Actual results may differ materially from the results anticipated in these forward-looking statements. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. Additional information on potential factors that could affect the Company's results and other risks and uncertainties are detailed in its Registration Statement on Form S-1/A, filed with the SEC on July 30, 2007, available at http://edgar.sec.gov.
Source: MAP Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.